United States Head and Neck Cancer Therapeutics Market, By Type (Diagnostic Methods (Biopsy, Imaging, Endoscopy, and Others), Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, and Targeted Therapy)), By Disease Indication (Lip & Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, and Hypopharyngeal Cancer), By Route of Ad
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited States Head and Neck Cancer Therapeutics Market, By Type (Diagnostic Methods (Biopsy, Imaging, Endoscopy, and Others), Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, and Targeted Therapy)), By Disease Indication (Lip & Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, and Hypopharyngeal Cancer), By Route of Ad
United States head and neck cancer therapeutics market is expected to grow at an impressive rate during the forecast period, 2024-2028 owing to the rising incidence rates of head and neck cancer, technological advancements, focus on immunotherapy, collaborative research efforts, increased awareness, and supportive regulatory and reimbursement policies.
The rising incidence of head and neck cancer in the United States is one of the primary drivers fueling the market expansion. The increase in incidents has been attributed to a number of causes due to tobacco use, excessive alcohol consumption, human papillomavirus (HPV) infection, and exposure to specific occupational hazards. Advanced therapies have been launched as a result of research and development efforts driven by the demand for efficient treatment alternatives for combating the problem.
The landscape of head and neck cancer therapeutics has gone through an evolution due to developments in medical technology. New therapeutic options have been made possible by the development of immunotherapies, targeted treatments, and precision medicine techniques. Genomic and molecular tests allow for the creation of personalized treatment programs for each patient, increasing the overall effectiveness of therapeutics. Additionally, improvements in radiation therapy and surgical methods have improved treatment outcomes and decreased side effects, spurring the market expansion.
Proactive programs for screening and increased awareness campaigns have assisted in detecting head and neck cancer early. Early diagnosis allows prompt action, which enhances the effectiveness of treatment. Additionally, campaigns to educate the public have emphasized the significance of risk factor modification, such as quitting smoking and drinking alcohol in moderation, to lower the frequency of preventable instances. The demand for efficient medicines has increased due to the focus on early detection and prevention.
The field of head and neck cancer therapeutics is seeing a growing interest in precision medicine, which involves modifying therapy regimens, based on a patient's genetic profile. Medical professionals may identify precise genetic changes and biomarkers that fuel tumor growth through developments in genomic testing and molecular profiling tools. Tyrosine kinase inhibitors and monoclonal antibodies, which specifically target cancer cells while minimizing harm to healthy organs, can be developed as a result of this information. Precision medicine's rising popularity is predicted to fuel the market by enhancing treatment outcomes and lowering adverse effects.
The field of head and neck cancer therapeutics may undergo a transformation due to the integration of artificial intelligence (AI) and big data analytics. To identify patterns, forecast treatment outcomes, and direct personalized treatment decisions, artificial intelligence can analyze enormous volumes of patient data, including medical records, imaging scans, and genomic profiles. This data-driven strategy has the potential to improve treatment approaches and advance precision medicine. The use of AI and big data analytics in clinical settings will boost the market and enhance patient outcomes.
Patient-centered care and supportive care services have become increasingly important in the treatment of head and neck cancer. Supportive treatment concentrates on treating complications of the drugs, enhancing patients' quality of life, and offering psychosocial support. Incorporating palliative care services to cancer therapy has been found to improve patient satisfaction and treatment compliance. The demand for supportive care services will increase, supporting market expansion as healthcare systems prioritize complete patient care.
There are some challenges that are hampering the growth of United States head and neck cancer therapeutics market. These challenges include high treatment costs, limited options for rare subtypes, resistance to therapy, treatment-related toxicities, regulatory hurdles, and limited awareness.
The cost of treating cancer, including head and neck cancer, appears to be a major issue. Targeted and immunotherapies are examples of novel medicines with substantial price tags. The total costs of these therapies are affected by the high cost of research and development, clinical trials, manufacturing, and distribution.
Significant side effects and toxicities can arise from the severe nature of head and neck cancer treatment, which typically involves surgery, radiation therapy, and chemotherapy. These might involve xerostomia, dysphagia, mucositis, and long-term side effects including persistent pain and swallowing issues. These side effects may have a significant negative influence on patients' functional results and quality of life. To enhance patient experiences and treatment adherence, efforts to minimize toxicities associated with the treatment must be made for the development of supportive care techniques.
Growing Incidences of Head and Neck Cancer
The incidence of head and neck cancer is on the rise worldwide, including in the United States, which is a major threat to public health. To improve treatment outcomes and improve patient care, there has been a lot of research and development due to the rise in cases. The expansion of the head and neck cancer therapeutics market in the United States is influenced by the rising incidence of head and neck cancer. ASCO estimates that 4% of all malignancies in the United States are head and neck cancers. A projected 66,920 individuals (49,190 males and 17,730 women) will be diagnosed with a head and neck cancer in 2023.
The prevalence of head and neck cancer is rising as a result of a number of factors, including tobacco use, excessive alcohol consumption, human papillomavirus (HPV) infection, and exposure to specific occupational dangers.
Pharmaceutical companies and academic institutions are continually investigating fresh medications and therapeutic approaches to treat head and neck cancer. A few of these developments are precision medicine approaches, targeted drugs, and immunotherapies that are customized to each patient's unique genetic profile and tumor features.
Clinical Trial Status
·
·
·
·
FDA Approvals
- Pembrolizumab (KEYTRUDA, Merck) was given FDA approval on June 10, 2019, to be used as the first-line treatment for people with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). The FDA approved the use of pembrolizumab as a single drug for patients whose tumors express PD-L1 (Combined Positive Score [CPS]] 1 as determined by an FDA-approved test) and in combination with platinum and fluorouracil (FU) for all patients.
Market Segmentation
The United States head and neck cancer therapeutics market can be segmented
Market Players
Merck & Co., Inc., Bristol Myers Squibb, AstraZeneca, Pfizer Inc., Eli Lilly and Company, Genentech, Inc., Amgen Inc., AbbVie Inc., Novartis AG are some of the leading companies operating in the market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2022 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume Units and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends |
| Segments covered | Type Disease Indication Route of Administration Therapeutic Class End User |
| Regional scope | Northeast Region; Midwest Region; South Region; West Region |
| Key companies profiled | Merck & Co., Inc., Bristol Myers Squibb, AstraZeneca, Pfizer Inc., Eli Lilly and Company, Genentech, Inc., Amgen Inc., AbbVie Inc., Novartis AG |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy